Long/short equity, biotech, healthcare, small-cap

Pacira Pharmaceuticals: Slow And Steady Wins The Race

Exparel, a product of Pacira Pharmaceuticals (NASDAQ:PCRX), is one of the leading non-opioid analgesics in pain management. Pacira is a rising specialty pharmaceutical company focused on hospital-based products for pain management. It is well known for its DepoFoam Technology, an injectable drug delivery technology that allows both immediate and sustained release of therapies. Its established product DepoCyt is used for treating cancer-related lymphomatous meningitis.

I believe that the company has tremendous growth potential due to its anesthetic product Exparel, which is currently approved only for use via surgical wound infiltration. The positive results from the first part of its Phase II/III study testing Exparel as a single-dose injection through femoral nerve block in patients undergoing total knee...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details